Jacobs Levy Equity Management
MRKR icon

Jacobs Levy Equity Management’s Marker Therapeutics MRKR Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,197
Closed -$46K – 1083
2020
Q4 		$46K Sell
3,197
-37
-1% -$574 ﹤0.01% 1003
2020
Q3 		$49K Buy
3,234
+961
+42% +$17.5K ﹤0.01% 1011
2020
Q2 		$47K Hold
2,273
– – ﹤0.01% 1023
2020
Q1 		$43K Sell
2,273
-12,555
-85% -$320K ﹤0.01% 982
2019
Q4 		$427K Buy
+14,828
New +$539K ﹤0.01% 805

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's MRKR Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Marker Therapeutics (MRKR) in Q1 2021, closing a stake of 3,197 shares — an estimated $46K sold.

Jacobs Levy Equity Management first reported a position in MRKR in Q4 2019 and held it in 5 quarters. The position peaked at $427K in Q4 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q1 2021.

  • Jacobs Levy Equity Management reported no remaining Marker Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,197 Marker Therapeutics shares in Q1 2021, an estimated $46K.
  • Jacobs Levy Equity Management first reported a position in Marker Therapeutics in Q4 2019 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Marker Therapeutics position peaked at $427K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.